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INTRODUÇÃO 
A epidemia causada pelo Vírus da Imunodeficiência Humana do Tipo 1 (HIV-1) 
está sofrendo grandes transformações tanto a nível epidemiológico como a nível 
molecular. No Brasil, o subtipo mais freqüente de HIV-1 é o subtipo B, mas, nos 
últimos dez anos, outros subtipos tais como F, C, e, as Formas Recombinantes 
Circulantes (CRFs) tem sido descritas [1,2]. Recentemente as CRFs 28 e 29, 
recombinantes entre clades B e F, foram caracterizadas e descritas no estado de 
Sâo Paulo [3] e a CRF 31, recombinante entre clades B e C, foi descrita na 
Região Sul [4].  
O HIV-1 subtipo C foi inicialmente identificado no Brasil em Porto Alegre, RS no 
início dos anos 90. Desde então, a prevalência do subtipo C na Região Sul 
cresceu de 3% em 1994, para 22% em 2000, atingiu 37% no ano de 2004 e 
chegou a 39% em 2007 [5]. Especula-se que o HIV-1C seja mais virulento a 
nível populacional que o HIV-1B [6]. Embora este fenômeno já tenha sido 
observado na África do Sul [7] e Índia [8] não há estudos conhecidos avaliando 
os fatores virológicos associados ao crescimento do subtipo C no sul do Brasil.  
Um maior conhecimento das características moleculares do HIV circulante e dos 
mecanismos da resposta imunológica na nossa população é fundamental para a 
compreensão da epidemia, desenvolvimento de produtos vacinais eficazes e 
para identificação de novas estratégias de prevenção e tratamento. Entretanto, 
para um melhor entendimento do crescimento do subtipo C se faz necessário 
estudar as características virais durante a fase aguda e recente, isto é as fases 
iniciais da infecção, quando o vírus ainda não se adaptou a resposta imune do 
hospedeiro.  
Aproximadamente, 35 milhões de pessoas estão infectadas pelo HIV [9], 
praticamente todas passaram por um período de infecção aguda (IAH).  Embora 
dezenas de milhares destes indivíduos tenham apresentado sintomas 
compatíveis com a síndrome retroviral aguda apenas poucos milhares de 
pacientes com IAH foram diangnosticados até hoje.  Historicamente, a 
dificuldade para identificar pacientes com IAH levou a uma falta de conhecimento 
sobre sua história natural e consequentemente incertezas sobre a necessidade e 
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o tratamento ideal [10].  Entretanto, novas tecnologias laboratoriais foram 
introduzidas, as quais tornaram o reconhecimento da IAH na rotina clínica uma 
realidade.  
Infecção aguda pelo HIV ou infecção primária é o primeiro estágio da doença 
causada pelo HIV. Nesta fase, o RNA do HIV ou carga viral pode ser detectado 
no sangue antes do aparecimento de anticorpos específicos.  A infecção primária 
pode ser diferenciada da infecção recente (quando a detecção de anticorpos é 
realizada por meio da utilização de ensaios imunoenzimáticos (EIE) comerciais, 
mas a concentração ou a avidez dos anticorpos ainda é reduzida); da infecção 
estabelecida, ou crônica, quando a resposta mediada por anticorpos está 
completamente desenvolvida.  Até 66% dos pacientes com IAH apresentam uma 
síndrome clínica inespecífica, autolimitada, semelhante à mononucleose, 
chamada de síndrome retroviral aguda [11-14]. Estudos sugerem que o período 
de incubação da IAH varia de 5 a 31 dias, contados a partir da exposição até o 
aparecimento dos sintomas, e possui uma duração média de 14 dias [11, 1-19]. 
Uma das principais características da síndrome retroviral aguda inclui o pico de 
viremia do HIV (tipicamente em milhões de cópias de RNA do HIV por mL de 
sangue) seguida, uma ou duas semanas mais tarde, pelo aparecimento de 
anticorpos ou soroconversão [19,20] e, um ou dois meses mais tarde, por uma 
diminuição expressiva da viremia plasmática [21].  O diagnóstico da IAH é 
dificultado pela ausência de anticorpos durante as primeiras semanas da 
infecção. Por isto, a avaliação laboratorial deve incluir testes que detectam 
ácidos nucléicos ou antígenos do HIV, como o antígeno p24.    
Estudos que avaliaram os testes necessários para o diagnóstico da IAH [15,16] 
indicam o uso de testes suplementares para detecção do antígeno p24 ou testes 
de amplificação dos ácidos nucléicos (TAANs) apenas em situações em que haja 
suspeita clínica de IAH.  Tais situações podem não ser tão incomuns como 
previamente assumido. Rosenberg e colaboradores [22] observaram que 1.0% 
dos pacientes com testes negativos para mononucleose infecciosa pelo vírus 
Epstein-Barr (VEB) apresentavam sorologia consistente com infecção aguda 
pelo HIV.  Pincus e colaboradores [23] observaram, em um serviço de urgência 
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da cidade de Boston (EUA), que 1.0% dos pacientes com “sintomas virais” 
apresentavam IAH, mesmo na ausência de suspeita clínica.   
Em estudo de revisão de 30 casos bem sucedidos de diagnóstico de IAH no 
estado da Carolina do Norte (EUA), Weintrob e colaboradores [24,25] relataram 
que a maioria dos pacientes necessitou retornar ao médico pelo menos três 
vezes até que IAH fosse considerada uma explicação para as queixas 
inespecíficas de síndrome retroviral aguda.  
Devido às dificuldades associadas ao reconhecimento clínico da IAH, as 
pesquisas na área tem focado na adaptação de algoritmos de testagem que 
permitam o uso de ensaios moleculares ou testes para detecção do antígeno 
p24 na rotina de triagem do HIV como testes suplementares.   
Nos ensaios moleculares disponíveis atualmente, o RNA do HIV ou carga viral, 
pode ser detectado com precisão em amostras de sangue periférico alguns dias 
após a infecção. A estratégia ideal compreende retestar as amostras anti-HIV 
negativas com metodologias moleculares. Este procedimento detectaria a maior 
parte dos casos de IAH nos indivíduos testados. No entanto esta estratégia é de 
alto custo e também eleva as chances de resultados falso-positivos [16]. 
Estratégias de testagem em grupo ou “pools” foram utilizadas, inicialmente, pelos 
bancos de sangue como uma solução para o elevado custo dos ensaios 
moleculares. Esta estratégia é baseada na criação de grupos ou pools de 
amostras de vários indivíduos.  Na triagem de grupos de amostras, o grupo que 
apresentar resultado positivo no ensaio molecular deverá ser desmembrado e 
suas amostras testadas individualmente. Os algoritmos de testagem em grupo 
reduzem o número de amostras individuais que necessitam testagem molecular, 
reduzindo o custo e, quando feita em níveis, também diminuem o potencial de 
resultados falso-positivos, aumentando a acurácia do processo de testagem.  
A aplicação da testagem em pools na triagem para o HIV foi primeiramente 
sugerida por Quinn, et al [26] e utilizada, prospectivamente, no programa público 
do estado da Carolina do Norte (EUA), na população de indivíduos que 
buscavam testagem para HIV no início do ano de 2002 [27]. Nos primeiros 12 
meses do programa de testagem suplementar com testes moleculares em pools 
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de amostras anti-HIV negativas um número adicional de 23 casos (4% das 
infecções identificadas no estado) apresentavam infecção aguda. 
Resultados similares foram obtidos em diversas populações urbanas que 
buscam testagem para HIV: São Francisco [25], Los Angeles [28], Atlanta [29] e 
Seattle [30] nos Estados Unidos e em Johannesberg [31], na Àfrica do Sul. Estes 
estudos indicam que a testagem de pools de amostras com TAANs pode ser 
uma alternativa promissora, entretanto, existem limitações nesta estratégia. Os 
TAANs são técnica e operacionalmente complexos, necessitam nível avançado 
de infra-estrutura laboratorial, de programas de qualidade e requerem que as 
amostras de sangue total sejam processadas previamente à realização do 
ensaio. Assim sendo, a estratégia de testagem de pools de amostras com 
TAANs pode não ser viável em áreas com limitada infra-estrutura laboratorial, ou 
situações onde a flebotomia convencional e o processamento de amostras 
possam ser problemáticos.  
Em situações em que a testagem em pools seguida de TAAN não seja viável, 
uma abordagem alternativa para melhorar a acurácia (valor preditivo positivo) e 
as questões de custo ligadas aos TAANs ou testes de antígenos virais é 
direcionar a testagem para populações com reconhecida alta prevalência de IAH.  
Estudos recentes avaliaram prospectivamente estratégias alternativas de triagem 
da IAH em áreas endêmicas como na Índia [13], Sul do Brasil [32], África do Sul 
[31] e Maláui [22, 33]. Os pesquisadores identificaram entre dois e três casos de 
IAH por 1.000 indivíduos nas suas respectivas populações de testagem. É 
importante salientar, que dois estudos [28,33] utilizaram ensaios do tipo enzime 
linked immunosorbent assay (ELISA) que detectam somente antígeno p24 para 
identificação de casos agudos e outro estudo [32] utilizou ELISA de quarta 
geração, ou seja, que detecta simultaneamente antígeno p24 e anticorpo anti-
HIV.  Esses estudos sugerem que a detecção de IAH, em larga escala, com 
métodos não-moleculares são viáveis mesmo em áreas do mundo com limitada 
infra-estrutura laboratorial.  
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Estudos para avaliar o desempenho de metodologias laboratoriais alternativas 
para a identificação de casos de IAH em áreas com alta prevalência do HIV são 
muito importantes para entendermos os mecanismos de transmissão do HIV e 
sua relação com a diversidade genética.   
A resistência a drogas anti-retrovirais pode ser dividida em duas categorias: 
transmitida ou primária, que ocorre quando um vírus que apresenta mutações 
associadas a resistência é transmitido para um indivíduo virgem de tratamento; 
adquirida ou secundária, que ocorre em indíviduos após um período de 
tratamento anti-retroviral. Embora os dois tipos sejam preocupantes, a 
resistência primária ao HIV tem o potencial de rapidamente reverter o eficácia do 
tratamento anti-retroviral a nível populacional.  
Os testes para detecção de resistência genotípica, comumente denominados de 
genotipagem, se tornaram uma ferramenta importante no monitoramento de 
pacientes infectados pelo HIV sob terapia anti-retroviral como também em 
situações para orientar a terapêutica inicial. Esse teste identifica as posições das 
mutações e/ou polimorfismos no genoma do HIV associados à resistência aos 
anti-retrovirais. Com o aumento global da diversidade genética do HIV surge a 
necessidade de vigilância sistemática da resistencia primária e a caracterização 
das mutações ou vias mutacionais de resistência dos subtipos circulantes em 
nossa população com o objetivo de garantir o sucesso dos programas de 
tratamento anti-retroviral.  
Casos de transmissão de vírus resistentes tem sido relatados nos últimos dez 
anos [34]. Estudos recentes sugerem que a prevalência da resistência primária 
no Brasil está sofrendo mudanças importantes com características regionais. Em 
estudo recente realizado no estado da Bahia, Pedroso [35] e colaboradores 
observaram uma prevalência de resistência primária de 18.9%. Sucupira [36] e 
colegas observaram uma prevalência de 36% em Santos. Por outro lado, estudo 
realizado no Rio de janeiro, em 2007, reportou prevalência de apenas 1.4% [37].  
Estudos que tenham a capacidade de integrar novos conhecimentos sobre 
metodologias laboratoriais eficazes, adequadas a nossa realidade e, novos 
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conhecimentos sobre a biologia da transmissão são vitais para o entendimento 
da epidemia e sua erradicação.  
Este trabalho faz parte de uma iniciativa do Laboratório de Pesquisa em 
HIV/AIDS da Universidade de Caxias do Sul (UCS), do Laboratório de 
Retrovirologia do da Disciplina de Doenças Infecciosas e Parasitárias da Escola 
Paulista de Medicina e de seus colaboradores em resposta a chamada de 
projetos de pesquisas International Research on Infectious Diseases (IRID) do 
Instituto Nacional da Saúde (NIH) do governo norte-americano. O Laboratório de 
Pesquisa em HIV/AIDS da UCS recebeu aprovação de financiamento do projeto 
com titulo em inglês de “Evaluation of HIV Subtype C Epidemic in South Brazil” e 
recebeu aprovação da Comissão Nacional de Ética em Pesquisa (CONEP) para 
este projeto.  
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OBJETIVOS 
1. Avaliar o desempenho de um ensaio imunoenzimático de quarta geração 
para detectar infecção aguda pelo HIV. 
2. Determinar a prevalência da resistência primária e descrever as 
características genotípicas do HIV-1 subtipo B e C entre os indivíduos 
virgens de tratamento que freqüentam Centros de Testagem e 
Aconselhamento Anônimos da Região Sul do Brasil. 
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Artigo 1  
Detection of Acute HIV Infection Using a Fourth-Generation 
EIA Screening Assay in Southern Brazil 
 
Ricardo S. de Souza,1,6, Robert W. Ryder2, Susan A. Fiscus3, Ada Cachafeiro3, 
M. Kerkau3, Luciene Scherer4, R.D. Sperhacke1,Simone Castro5,  , Ricardo 
Sobhie Diaz6, and Christopher D. Pilcher 7 
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University School of Public Health, Boston MA; 3Center for AIDS Research, 
University of North Carolina at Chapel Hill, Chapel Hill, United States, 4Fundação 
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Retrovirologia, Universidade Federal de Sâo Paulo, Sao Paulo, Brazil and 
7HIV/AIDS Division, Universiity of California-San Francisco, San Francisco, 
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Abstract 
Detecting acute HIV infections is an important HIV prevention goal. ‘Fourth-
generation’ enzyme immunoassays (EIAs) detect both HIV antibody and HIV 
antigens. We compared fourth-generation EIA, antibody-only third generation and 
HIV RNA assay performance using 933 specimens collected consecutively from 
HIV testing clients in south Brazil. The fourth-generation assay detected 183 HIV 
infections (subtype B and C) with 100% sensitivity and 99.8% specificity. The 
antibody testing algorithm failed to identify three cases of acute HIV infection 
(1.6% of confirmed cases). These results suggest that fourth-generation EIA 
based screening may have sufficient accuracy to facilitate acute HIV based 
prevention strategies in resource limited, high prevalence settings with diverse 
HIV subtypes. 
 
 
Key Words:  Acute HIV infection, Fourth-generation EIA, pooled HIV RNA, HIV 
screening. 
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Introduction 
Acute HIV infections (i.e., those occurring in the previous 1-3 months, when 
standard HIV antibody tests remain negative) have been estimated to account for 
as many as half of all HIV transmission in some populations [1].  Recent studies 
demonstrating that antibody negative acute cases may represent between 4% to 
39% of infected patients presenting for HIV testing have further highlighted the 
potential importance of targeted treatment, surveillance and prevention activities 
focusing on acute infection [2-4]. To date, most experience with testing for recent 
HIV infection has relied on “detuned”, less-sensitive antibody assays calibrated to 
identify antibody positive individuals with recent seroconversion on the basis of 
low titer and/or low affinity antibodies [5]. Another used method, the BED capture 
enzyme immunoassay is based on the increasing proportion of anti-HIV1 IgG in 
total IgG following seroconversion [6]. However, such assays diagnose new 
infections with a 1-2 month delay and do not identify acute infection. 
Techniques for real-time diagnosis of acute HIV at HIV testing, adding screening 
tests for HIV antigens (e.g., p24) or nucleic acids (HIV RNA) to antibody testing 
algorithms have been explored [7-9].  The gold standard for AHI (acute HIV 
infection) diagnosis remains HIV RNA testing, which is highly sensitive and can 
be made both efficient and accurate through the use of pooling strategies [10].  
However, HIV p24 antigen assays are more rapid, less expensive and less 
technically demanding [11], and have been used with some success to identify 
AHI cases in high incidence HIV testing populations, achieving up to 75% 
sensitivity when compared to a reference standard including HIV RNA [12].  For 
HIV screening, it is important to emphasize that p24 or HIV RNA are 
supplemental tests: specimens are first classified as antibody negative, positive 
or indeterminate using a classical screening/confirmatory antibody testing 
algorithm.  If antibody negative or indeterminate, they can then be screened for 
nucleic acid or antigen. This strategy increases window period case identification 
but increases the cost of screening for AHI and the turnaround time of results. 
Fourth-generation HIV enzyme immunoassays (EIA) were developed by the 
blood screening industry in the 1990s to detect both antigen and antibody 
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simultaneously [13].  Although they have found limited use in blood screening, 
they have several potential advantages for HIV testing in the clinical setting.  
They are highly sensitive for detection of HIV during the window period of AHI: 
testing on seroconversion panels suggests that commercially available fourth-
generation assays can detect AHI within 3 days after these infections are first 
detectable by HIV RNA testing [14]. They can also be performed easily with 
several hours’ turnaround time using equipment available in many HIV 
laboratories in the developing world.  Interestingly, the clinical performance of 
these assays has not been well studied.   
In this study we evaluated the ability of a fourth-generation EIA to detect acute 
HIV infection in comparison to HIV RNA, in an HIV testing population in southern 
Brazil, an area with mixed subtypes and a recognized increase of the HIV-1 clade 
C [15]. 
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Subjects, Materials and Methods 
We conducted a retrospective, cross-sectional, diagnostic performance 
evaluation involving plasma samples submitted for analysis to the Vila dos 
Comerciários (VCC) Health Clinic (Porto Alegre, Brazil) and anonymized for 
completion of performance evaluation. Individuals seeking routine anonymous 
HIV voluntary counseling and testing at VCC were screened for HIV. Clients with 
inconsistent results on this testing were counseled as HIV indeterminate and had 
confirmatory testing performed. All clients completed a routine questionnaire 
detailing demographics and HIV risk factors at the time of specimen collection.  
Consecutive samples were collected from patients that had received routine HIV 
testing from the VCC voluntary and counseling testing center between January 
and March 2004. Initial HIV testing was performed by the VCC laboratory. All 
specimens having negative or indeterminate specimens results were anonymized 
by the VCC lab, associated with a study code and submitted to the Virology 
Laboratory at the University of North Carolina at Chapel Hill, USA (UNC) for 
additional HIV RNA screening. Antibody negative or indeterminate specimens 
from subjects of all ages and genders were transferred. For purposes of data 
analysis, the VCC laboratory provided the study team with initial HIV testing 
results and limited additional information (gender, age, and follow-up confirmatory 
HIV test results) for all clients screened during the study period.  
HIV testing by the VCC laboratory was carried out using a fourth-generation HIV 
EIA (Genscreen Plus HIVAg-Ab; Biorad, Hercules, CA, USA), which detects HIV 
p24 antigen and anti-HIV.  This assay has been in use at the VCC laboratory 
since 2003.  For specimens that were positive on the fourth-generation HIV test, 
the VCC laboratory performed immediate confirmatory anti-HIV testing using 
three different anti-HIV tests in parallel: the Axsym HIV1/2 gO MEIA (Abbott 
Laboratories, IL, USA), a  third generation EIA; the indirect immunofluorescence 
assay (IFA) from Biomanguinhos (Fiocruz, Rio de Janeiro, Brazil); and the 
Determine HIV rapid test (Abbott, Abbott Park, IL, USA).  Western blot (WB) (HIV 
Blot 2.2, Genelabs Diagnostics, Singapore) was performed to help resolve cases 
with inconsistent or low-signal positive antibody testing results, and was 
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interpreted according to Centers for Disease Control and Prevention (CDC) 
criteria [16].  
Specimens found to be negative using the fourth-generation EIA were screened 
for HIV RNA at the virology laboratory at UNC using the Roche assay (Amplicor 
Monitor HIV RNA version 1.5; Pleasanton, CA, USA) and a 1:12 robotic minipool 
strategy after the technique of Busch and colleagues [17]. Specimens that were 
positive on the fourth-generation EIA but negative or indeterminate on one or 
more follow-up anti-HIV test were submitted for individual HIV RNA testing if 
specimen remnants were available.  Following all HIV RNA testing, RNA positive 
specimens were then submitted for population sequencing of pol for preliminary 
HIV subtype analysis (ViroSeq™ v2.0, Celera Diagnostics, Alameda, California, 
USA).   
HIV infection status was determined using all available data. HIV negative status 
was defined by having consistent negative results on all testing. Acute HIV 
infection (AHI) was defined by having one or more negative antibody screening 
tests results, with infection status supported by a positive HIV RNA result or 
documented seroconversion. Established HIV Infection was defined by having 
consistently positive results on confirmatory antibody testing.   
Diagnostic performance of the fourth generation EIA and routine antibody EIA 
screening assays were assessed using a reference standard that included all 
detectable HIV infections, according to the above definitions (rather than only 
antibody-positive infections). Sensitivity, specificity and positive and negative 
predictive values were calculated with 95 percent confidence intervals. Analyses 
were conducted using SAS (version 8.2; SAS Institute).  
All study procedures were approved by the human subjects review boards of the 
University of Caxias do Sul and the University of North Carolina School of 
Medicine.  
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Results 
In total, 933 consecutive specimens were received by the VCC laboratory during 
the study period. The majority of those seeking testing were men (61%) between 
the ages of 5 and 64, with a mean age of 31.9 years. Females comprised 39% of 
the group with a mean age of 32.5 years. The study’s HIV screening procedures 
are illustrated in Figure 1. Of 933 specimens screened, 932 were fully evaluable 
and 181 (19.4%) of these were confirmed as HIV infected by the complete 
algorithm.  One specimen (with results suggesting probable, but unconfirmed 
acute HIV infection) was not able to be classified according to our study 
definitions, and was excluded from the primary analysis.  
All confirmed HIV infections were positive on the fourth-generation EIA; none of 
the 750 confirmed fourth-generation negative specimens tested positive for HIV 
RNA.    
Five fourth-generation EIA positive specimens had negative or inconsistent 
results on confirmatory antibody testing (see Table 1). Of these 5 possible acute 
cases, 3 (A,B,C) were repeatedly HIV RNA positive meeting the study definition 
of acute HIV infection.  A fourth possible acute case (D) had no remnant 
specimen available for confirmatory RNA testing   and no documentation of 
seroconversion and was unclassifiable.  The final case (E) had insufficient 
sample but did follow-up and failed to seroconvert by any assay 30 days after the 
first test, and was classified as HIV negative.  
Two of the three RNA positive acute cases were sequenced. One was found to 
be HIV subtype B and the other a recombinant CB. 
The overall prevalence of acute HIV infection in the study population was 0.32% 
(3/932), representing 1.6% of all confirmed HIV infections.  Considering all 
evaluable specimens, the sensitivity (Se) of the fourth-generation EIA for HIV 
infection in this study was 100.0% (95% confidence interval: 98.3,100.0) and the 
estimated specificity (Sp) was 99.8% (99.2,100.0). Positive predictive value 
(PPV) was 99.4% (96.9,100.0) and negative predictive value (NPV) was 100.0 % 
(99.6,100.0).  
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The sensitivity of antibody assays for confirmed HIV infection varied 
(immunoflourescence, 98.3%; third generation EIA, 99.4%, rapid test 100%); 
several false-positive antibody test results were noted, but the specificity, PPV 
and NPV of these assays were not evaluable in this study.  
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Discussion 
In a clinic setting with high HIV prevalence in Southern Brazil, the fourth-
generation EIA assay accurately identified 1.6% of HIV cases that were missed 
by standard antibody tests and showed a high specificity (99.8%). The proportion 
of acute (antibody-negative) cases found in this testing population was in accord 
with findings of other studies in high risk populations that have used HIV RNA-
based testing [12,9].  We were unable to demonstrate an advantage to including 
HIV RNA screening over and above the fourth-generation EIA for detection of 
acute HIV infections.  These results suggest a simple, low-tech alternative to HIV 
RNA screening for accurate identification of acute HIV infections in resource-
constrained settings with a high burden of HIV infections. 
We demonstrated the assay’s high sensitivity and specificity in a population with 
mixed HIV subtypes: in a separate report working with the same specimens, 
Rodrigues and colleagues [21],documented that 32% of the HIV infections in this 
study were of subtype B, 58% were subtype C and 3% were F recombinants. 
High sensitivity across HIV subtypes is likely typical of the current generation of 
such tests [18]. The limits of detection of modern fourth-generation assays range 
from 3 to 10 pg of p24 Ag/ml, comparable to those for p24 Ag-only assays [19], 
and they accordingly reduce the seroconversion window period to around 2 
weeks, within 3 days of (non-pooled) HIV RNA assays [20]. High specificity 
(99.8%) of our study’s screening assay has been reported previously [18] and is 
superior to the reported specificities of many antibody screening tests in current 
use. 
The method used in this study confers some potential advantages in closing the 
window period for HIV infection.  First, the fourth-generation screening assay is 
typically used as a primary screening test, and supplemental (antibody-only) 
testing is only performed on the small number of samples that screen positive by 
the fourth-generation test. By contrast, combined antibody/RNA or antibody/p24 
screening algorithms demand that both antibody-negative and antibody-positive 
results be confirmed with some form of supplemental testing before results can 
be reported. Thus, using the fourth-generation assay ‘up front’ dramatically 
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reduces the number of specimens to be retested. This potential advantage may 
be of less impact in testing populations with very low HIV prevalence, where 
specimen pooling/RNA algorithms can be highly efficient [7]. In high prevalence 
settings, however, specimen pooling/RNA algorithms are unlikely to approach the 
testing efficiency of fourth-generation EIA-based testing [10]. 
Second, fourth-generation EIAs are relatively simple, suitable for testing sizable 
numbers of samples, and easily adapted to automated platforms. Their list price 
is similar to that of third-generation assays, making their use feasible in resource-
limited settings.   
Third, some new fourth-generation assays [14] read detection of antigen and 
antibody as separate results—allowing probable acute and 4established cases to 
be distinguished in one single simple assay. This could dramatically reduce the 
turnaround time for identification and confirmation of suspected acute cases.   
Fourth, nucleic acid based test may be potentially more problematic than EIA 
based tests in places were more genetically diverse HIV circulates, since nucleic 
acid tests sensitivity relies in the efficient annealing of primers and probes.   
If the performance and cost-effectiveness of fourth-generation EIAs are borne out 
in larger studies, the results of this study suggest that the expanded use of fourth-
generation assays by public health programs could help create important 
opportunities for acute HIV-centered prevention without the need for complex 
specimen pooling and nucleic acid amplification. Projecting the use of the fourth-
generation EIA in the Brazilian epidemic by applying the number of HIV tests 
performed in the country and the reported prevalence of HIV infection, we 
estimate that as many as 2,500 (acute) cases presenting for testing in Brazil have 
been missed from 2000 to 2005.  
We recognize that the small number of samples constitutes a limitation of the 
present study. However, methods to reliably identify acute HIV infection are 
urgently needed to develop strategies focusing on reducing HIV transmission by 
individuals with acute HIV infection. Our results suggest that simple, fourth-
generation EIA screening can detect acute HIV infections with sufficient accuracy 
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to make acute HIV based prevention strategies feasible in high HIV prevalence, 
resource limited settings with diverse circulating HIV subtypes. 
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Figure and Tables Legends 
Figure 1: Flow chart of the Screening Procedures for Combined HIV antigen and 
antibody (fourth-generation) and antibody-only EIAs in a Testing Site in Southern 
Brazil.  
Figure Sublegend:   
4th Gen EIA: Fourth generation enzyme immunoassay (EIA) 
3rd Gen EIA: Third generation enzyme immunoassay (EIA) 
IFA: Indirect immunofluorescence assay 
RT:  Rapid test 
WB: Western Blot 
QNS: Quantity not sufficient 
 
Table 1: Classification of AHI According to Test Results and Follow up 
Information.  
Table Sublegend:  
ID: Specimen identification 
4th Gen EIA: Fourth generation enzyme immunoassay (EIA) 
3rd Gen EIA: Third generation enzyme immunoassay (EIA) 
IFA: Indirect immunofluorescence assay 
RT:  Rapid test 
WB: Western Blot 
ND: Not done 
Indet: Indeterminate 
QNS: Quantity not sufficient 
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Figure 1. 
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Table 1. 
 
ID 
4th 
Gen 
EIA 
3rd 
Gen 
EIA 
IFA RT WB 
HIV 
RNA 
Subtype 
Sero-
conversion 
Acute 
HIV 
A + + - + + + CB Yes Yes 
B + - - + ND + QNS 
No 
information 
Yes 
C + + + + Indet + B Yes Yes 
D 
 
+ 
 
+ + - - QNS QNS 
No 
information 
Not 
confirmed 
E + - - + ND QNS QNS No No 
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Abstract 
Background: A growing epidemic by clade C viruses is occurring in the south of 
Brazil. We sought to characterize the prevalence of transmitted HIV-1 among 
newly diagnosed, ARV-naive HIV infections in the epicenter of the Brazilian clade 
C epidemic.  
Methods: We studied 114 consecutive HIV positive samples collected from 
October 2006 to August 2007 at 4 anonymous HIV testing sites participating in 
Projeto AMPLIAR in Rio Grande do Sul, Brazil. HIV-1 pol regions were 
compared, with antiretroviral resistance defined by genotypic analysis. Recent 
infections were characterized by the BED CEIA incidence assay. 
Results: 15 of 114 (13%) HIV+ were classified as recently infected. 8.3% of 
those with recent infection and 11,2% of long term infections showed resistance 
to at least one antiretroviral class. Considering pol sequences, 63% of individuals 
were infected by clade C viruses, 27% were infected by clade B, and 10% by 
non-B non-C strains; proportions of recent infection were similar across subtypes. 
The prevalence of primary resistance was 5.5% among clade C infected vs. 
19.3% among clade B infected, and vs. 18% among non-B non-C infected 
individuals. The odds of resistance were higher among HIV positives with 
subtype B and non-B non-C (p=0.03).  41% of patients with resistance mutations 
showed resistance to NRTI, 40% had TAMs, 60% had other NAMs, and 8.3% 
showed resistance to PIs. 
Conclusions: In south Brazil, where clade C infections have over-grown non-C 
infections, clade C viruses appear to show a low frequency of primary ARV 
resistance.  These observations may be explained in part by more recent 
introduction of clade C to south Brazil; by less diagnosis or ARV use in 
populations affected by clade C (heterosexuals); by the relative inability of 
recognizing the correlates of antiretroviral resistance in non-B strains; and/or by 
other biologic factors.  
 36
Introduction 
Human Immunodeficiency Virus Type 1 (HIV-1) genetic diversity is a hallmark of 
HIV-1 infection and is characterized by three classes and nine major subtypes 
distributed in geographical regions of the world. HIV-1 subtype B has 
predominated in the developed Western world and in most Latin American and 
Caribbean countries, but an increasing number of non-B infections, including 
subtypes F, C, D, and E [1-7], B/F recombinant [8,9] and mixed HIV-1 infections 
[10]  have been reported in these regions.  Subtype C predominates in southern 
Africa [11] and India [12] and is increasing in frequency in China [8,9] and south 
Brazil [13,14]. HIV-1 subtype C now accounts for >56% of all circulating viruses 
and is the most commonly transmitted subtype worldwide [15].  HIV-1 subtypes 
also differ in its biological properties. These characteristics may influence 
infectivity, transmissibility, disease progression and response to antiretroviral 
treatment.  
Antiretroviral resistance is a major concern in developed and developing 
countries due to its potential impact on therapeutic strategies. Theoretically, 
Individuals with transmitted drug resistance begin antiretroviral therapy with a 
lower genetic barrier to resistance and have a higher risk of virologic failure. On 
the other hand, transmitted drug resistant mutations compromise the replicative 
capacity of drug resistant virus, and reduce viral transmission efficiency [16-18].   
The disproportionate increase in C viruses relative to other HIV-1 strains 
suggests that subtype C may be more easily transmitted or that it has a higher 
level of transmission "fitness" at the population level.  
Brazil’s universal access to antiretroviral therapy (ART) has been remarkably 
successful since its introduction in 1996 and as with many antiretroviral treatment 
programs drug resistance is emerging. Despite reports of high level of secondary 
resistance [19], overall transmitted resistance seems to be low in Brazil [20] 
However, high levels of transmitted resistance have been reported in specific 
regions of the country [21,22]. The Brazilian National AIDS Program (NAP) in 
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collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) 
developed the AMPLIAR program to collect prospective representative data to 
monitor and to study the epidemiology and the biology of HIV in the most affected 
region of the country. The co-circulation of HIV-1 subtype B, C and recombinant 
forms in the south region of Brazil provides a unique opportunity to study the 
dynamics of HIV infection within the same population.  
In order to assess viral characteristics potentially associated to the increase of 
HIV-1 subtype C in southern Brazil we compared the prevalence of transmitted 
drug resistance among individuals with newly diagnosed HIV infection caused by 
subtype B, C or recombinant strains in the AMPLIAR program. In addition, given 
that many drug resistance mutations may compromise the replicative capacity of 
the virus and might reduce transmission efficiency compared to wild-type virus 
we analyzed the rate of HIV subtype B, C and mosaic infections in patients with 
recent HIV-1 and compared it with the prevalence of HIV infections caused by 
these clades in a group of individuals who were potential transmitters of HIV-1, all 
of whom were living in the same geographical area and seeking HIV testing at 
the AMPLIAR clinics. 
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Methods 
Setting and Study Design 
The AMPLIAR 010 protocol is a diagnostic prospective cohort study conducted in 
four HIV voluntary counseling and Testing centers (VCT) in southern Brazil. 
Enrollment began in November 2006, and is ongoing. 
Study Subjects 
We evaluated consecutive individuals presenting for HIV testing at public VCTs in 
the state of Rio Grande do Sul covering approximately 45% of the state testing 
population. Study population was subjects seeking HIV testing > 16 years old, 
newly diagnosed with HIV infection between November 2006 and August 2007 
(n=1255) and with no history of previous HIV diagnosis. Eligible individuals are 
considered antiretroviral (ARV) naïve. 
Testing and results disclosure were carried out according to Brazilian National 
AIDS Program (NAP) guidelines. Demographic and risk behavior information 
were obtained at each visit from data collection forms, administered individually 
by trained counselors during the HIV voluntary counseling and testing 
procedures. At each visit laboratory specimens were collected.  
Testing Algorithm 
HIV testing was carried out using a fourth-generation HIV enzyme-linked 
immunoassay (EIA) which detects HIV p24 antigen and anti-HIV (Genscreen Plus 
HIVAg-Ab; Biorad, Hercules, CA, USA) simultaneously. For specimens that were 
positive on the fourth-generation assay, confirmatory anti-HIV testing using three 
different anti-HIV tests were done in parallel: the Axsym HIV1/2 gO MEIA (Abbott 
Laboratories, IL, USA), a third-generation EIA; the indirect 
immunofluorescenceassay (IFA) from Biomanguinhos (Fiocruz, Rio de Janeiro, 
Brazil); and the Determine HIV rapid test (Abbott, Abbott Park, IL, USA).  
Western blot (WB) (HIV Blot 2.2, Genelabs Diagnostics, Singapore) was 
performed to help resolve cases with inconclusive testing results, and was 
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interpreted according to Centers for Disease Control and Prevention (CDC) 
criteria [23].  
Specimens found to be negative using the fourth-generation EIA were screened 
for HIV RNA (Roche Amplicor Monitor HIV RNA version 1.5; Pleasanton, CA, 
USA or Versant HIV 3.0; Bayer Diagnostics, Emeryville, California, USA) in a 
1:20 manual pool strategy after the technique of Busch and colleagues [24]. 
Specimens that were positive on the fourth-generation EIA but negative or 
indeterminate on one or more follow-up anti-HIV test were submitted for 
individual HIV RNA testing.   
HIV laboratory staging and molecular characterization 
HIV infection status was determined using all available data. Acute HIV infection 
(AHI) was defined by having one or more negative antibody screening tests 
results, with infection status supported by a positive HIV RNA result or 
documented seroconversion. HIV antibody-positive specimens were further 
characterized as recent HIV infections by BED-Capture enzyme immunoassay 
[25]. Specimens were tested at the HIV Research laboratory at the Universidade 
de Caxias do Sul, located in Caxias do Sul, Rio Grande do Sul, Brazil. Plasma 
was stored at -70C for batched genotypic analysis at the Retrovirology 
Laboratory at the Federal University of Sao Paulo, located in Sao Paulo, Brazil. 
Viral RNA was extracted from plasma and complementary DNA synthesis was 
carried out with random primers as described elsewhere [19].  The protease (PR) 
and reverse transcriptase (RT) regions were amplified, purified and sequenced 
using an automated sequencer. Identification and analysis of antiretroviral 
resistance mutations were performed according to suggested consensus [26]. 
Statistical Analysis 
Demographic, behavioral and clinical information (age, gender, schooling, marital 
status, exposure category, HIV subtype, number of sex partners in the last 12 
months, HIV viral load and HIV laboratory staging) were assessed using chi-
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square and Fisher’s exact statistical test. Sequences were grouped according to 
their assigned HIV-1 subtype. Existing mutations were grouped according to 
antiretroviral class nucleoside/nucleotide RT, non-nucleoside RT or protease 
inhibitors. The prevalence of HIV resistance mutation was estimated as the 
proportion of the samples tested that presented specific mutations. The average 
number of mutations and the prevalence of resistant strains in the three classes 
was compared by HIV-1 subtypes. Analyses were conducted using STATA 
version 10 (Stata corp, Texas). 
Transmission Efficiency Analyses 
The estimation of transmission efficiency for HIV subtype was represented as a 
ratio originated from dividing the rate of a specific HIV clade in the group of 
participants with laboratory evidence of recent HIV infection by the corresponding 
rate found in the potential transmitter group. This ratio was applied to HIV 
subtype groups (B, C and Mosaic). In this experimental analysis, a ratio of 1 
means a relative transmission efficiency of 100%. The potential transmitter group 
consisted of individuals with long-term HIV infection living in the AMPLIAR 
program catchment area who had plasma HIV RNA levels >1000 copies/mL [27]. 
Ethical considerations 
Signed informed consent was obtained for all subjects prior to enrollment into the 
study. The protocol was approved by the ethical review board at each clinical 
site, as well as by institutional review boards at the Universidade de Caxias do 
Sul and the University of California San Francisco. 
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Results 
Patient Population 
Of the 1255 participants seeking HIV testing, there were a total of 149 newly 
detected HIV infections. Newly identified cases represented 11.9% of the testing 
population. On the basis of the BED-CEIA and discordant antibody and antigen 
results we classified 15 (10%) recent HIV infections and 134 long-term infections 
(Figure 1). The use of NAAT in HIV antibody negative specimens did not identify 
additional cases of infection. Men compromised 54% of the testing population, of 
which 27% were men who have sex with men (MSM). Prevalence of HIV was 
higher for MSM (22%, OR 2.5, CI 1.4 to 4.5) than non-MSM. Among non-MSM, 
having HIV was positively associated with less schooling (OR 2.0, CI 1.4 to 2.9). 
Table 1 summarizes major demographic and behavioral characteristics for 
subjects with and without transmitted drug resistance mutations.  
Subtyping results 
Of the 149 HIV infections, 8 (5.3%) specimens had undetectable HIV RNA load 
and were not sequenced. One hundred and fourteen (81%) of the 141 HIV 
infected participants with detectable viral load were screened for infecting HIV-1 
subtype sequence analyses of partial pol sequences. Of these, 72 (63%) were 
subtype C, 31 (27%) were subtype B. The 11 (10%) remaining viral isolates 
corresponded to subtype F (n=5), recombinant forms F/B (n=5), and A (n=1). 
Having a C vs a non-C virus was associated with being a heterosexual male vs 
MSM (OR 3.5, CI 1.0 to 12.4). 
Genotyping results 
The prevalence of mutations at amino acid sites associated with drug resistance 
among newly diagnosed drug naive individuals was present in 12 (10,5%) 
subjects (Table 2). Mutations conferring drug resistance were present in 11 
subjects with long-term infections and one in a recent HIV infection. We observed 
a differential pattern of drug-resistant among HIV clades. Four cases (5,5%) were 
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found in subtype C and 6 cases (19,3%) in subtype B (Figure 2 and Table 2). We 
further examined the frequencies of transmitted drug resistance in subtype B and 
C and analyzed mutations according to antiretroviral class (ARV). Overall, 
mutations conferring resistance to non-nucleoside reverse transcriptase inhibitors 
(NNRTI) were the most prevalent, occurring in 7 (58%) cases. Five (41%) had 
nucleoside reverse transcriptase inhibitor (NRTI) mutations. Of these, 40% had 
Thymidine Analogue-associated Mutations (TAMs) and 60% had other 
Nucleoside Analogue-associated Mutations (NAMs). Dual class resistance was 
present in one (8,3%) case. Table 2 presents the frequency of mutations 
according to ARV class and Table 3 depicts the specific mutations detected 
according to subtype.  
Transmission Efficiency of HIV-1 Subtypes 
The proportion of recently infected subjects with subtype B and C was 19% and 
11%, respectively. Overall, transmission efficiency was lower for subtype C 
viruses compared to subtype B. Interestingly, when drug resistance viruses were 
excluded from the analyses and only wild type virus was considered, the 
transmission efficiency rate increased in 25% for subtype B and 16% for subtype 
C. The effect of drug resistance on HIV subtype transmission efficiency is shown 
in Figure 3A (all viruses) and 3B (wild type only). The sample size was too small 
to draw conclusions from the analyses restricted to drug resistant virus (data not 
shown).  
The reduced transmission efficiency observed in individuals with drug resistant 
virus, despite HIV subtype, could be explained by a lower average plasma HIV 
RNA load than seen in individuals harboring wild type virus. To test this 
hypothesis, we compared the HIV RNA for subtype B and C with and without 
drug resistance mutations. Comparisons of plasma HIV RNA (median log10 
copies/mL) load in subjects with subtype B and C did not differ despite the 
presence or not of drug resistance mutations. However, we observed a trend 
toward lower HIV RNA levels in subjects with subtype C. The median log10 
copies/mL was 4.35 for subtype C and 4.91 for subtype B.  
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In addition, we observed that the transmission efficiency of HIV subtype C was 
lower than subtype B (Figure 3A and 3B). This would not explain the expansion 
of subtype C seen in our region in the last ten years. In order to understand the 
observed lower transmission efficiency seen in subtype C, in the context of an 
expanding subtype C epidemic in the region, we estimated the proportion of wild 
type B and C viruses in the population and multiplied it by the transmission 
efficiency ratio. In the proposed model (Table 4) the risk of infection by  subtype 
C is greater than for subtype B (8.82% vs 6.54%, p=0.17). This observation could 
suggest a competitive advantage of subtype C, at a population level, when 
compared to subtype B and partially explain its fast expansion in southern Brazil.  
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Discussion 
  Primary HIV antiretroviral resistance is an important clinical and public health 
problem. The presence of resistant mutants prior to therapy contributes to a rapid 
emergence of resistance when therapy is introduced [30]. To date, however, few 
data are available as to how subtype diversity may affect HIV transmission and 
the role of transmitted drug resistance mutations in this process. 
We found a relatively low prevalence of transmitted drug resistance and a 
marked differential pattern of drug resistance among HIV clades. In our study, 
subtype C was 3 times less likely to harbor drug resistance mutants compared to 
subtype B.  
Phylogenetic analysis from Brazilian subtype C strains reveals a monophyletic 
group strongly related to African and Indian viruses but with a unique signature 
sequence, suggesting that subtype C entered the country as a single 
introduction, or a small group of genetically related viruses in the mid 1980s [28].  
The lower prevalence of drug resistance acquisition in HIV-1 subtype C combined 
with the preferential selection to NNRTI mutations in this subtype may be 
explained by the recent introduction of this subtype in the south region of Brazil. 
Its plausible to speculate that HIV subtype C was less exposed to ARVs than 
subtype B. 
Acquired drug resistance in antiretroviral experienced patients has been shown to 
be differentiated by HIV subtype. In a recent study, subtype C was less prone to 
fix mutations associated to drug resistance over time when compared to other B 
subtypes from patients experiencing the same type and length of ARV exposure 
[28]. It is conceivable that differences in drug resistance acquisition reported in 
this study could be, in part, related to the existence of background transmitted 
mutations, as reported in our study. In addition, it has been suggested that sexual 
transmission of HIV selects for highly fit drug-resistant variants that persist for 
years [29]. 
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The rapid spread of HIV subtype C viruses [4] worldwide has been interpreted as 
indirect evidence for higher transmission efficiency of subtype C strains, although 
the viral and host factors underlying subtype C spread are poorly understood. 
However, it is increasingly evident that additional (nonhost) viral factors are also 
contributing to the rapid spread of HIV-1 C. Viral studies indicate that subtype C 
has distinct genetic and phenotypic properties that differentiate it from other HIV-
1 subtypes. These genetic properties may influence viral gene expression, 
altering the pathogenesis of C viruses.    
The transmission efficiency analyses proposed in our study are in agreement with 
other studies that observed that many drug resistance mutations compromise the 
replicative capacity of the virus [16]. However, specific drug resistance mutations 
that particularly affect viral fitness [17,18] might impair transmission in different 
ways. The observed smaller rate of transmission efficiency for subtype C is 
unexpected. An important factor that might be contributive to this finding is the 
viral load of the subjects studied. We observed reduced viral load in individuals 
infected with subtype C when compared to subtype B, however not significant. 
Our study has some limitations. First, the frequency of HIV-1 drug resistance and 
acute/recent infection were too small for meaningful statistical comparisons. 
Second, the utilization of NAAT for the screening of HIV negative individuals did 
not identify additional cases of infection. This finding may be explained by the 
small number of patients screened, by the fact that we used a fourth generation 
assay for the screening procedures and alternatively by the late presentation for 
testing seen in our study population. Third, we made a series of assumptions to 
allow for the transmission efficiency estimation and the calculation of HIV subtype 
risk in the population. An additional aspect related to subtype C in Brazil is the 
high frequency of amino acid polymorphisms at positions associated to 
secondary resistance mutations to protease and reverse transcriptase inhibitors. 
Although experimental evidences of the impact of these substitutions in subtype 
C viruses on resistance to protease inhibitors (PI) available and widely used in 
Brazil is unknown [31] in our study we restricted our analyses to primary 
mutations in subtype C. 
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 The lower prevalence of transmitted drug resistance of HIV-1 C could be relevant 
to surveillance and treatment programs in developing countries, especially in 
Africa. In conclusion, In the South region of Brazil HIV-1 non B clades are the 
majority (73%), with a growing prevalence of clade C infected individuals (63%). 
The prevalence of primary resistance is relatively low in this region with the 
absence of multi-class resistance strains. These observations may be explained 
in part by a more recent introduction of clade C in the south region of Brazil; by 
less diagnosis or ARV use in populations affected by clade C (heterosexuals); by 
the relative inability of recognizing the correlates of antiretroviral resistance in 
non-B strains; and/or by other biologic factors.  
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Figures and tables legends 
Figure 1: Testing algorithm for detecion of HIV-1 infection and transmitted 
antiretroviral resistance in the AMPLIAR Program  
RNA - : undetectable viral load 
Ab - : HIV antibody negative 
Ab + : HIV antibody positive 
 
Figure 2: Overall prevalence of transmitted drug resistance mutations in 
newly diagnosed antiretroviral naive individuals in South Brazil (A) and 
prevalence of drug resistance mutations for HIV subtype B and C according 
for NRTI and NNRTI (B). 
NRTI: nucleoside reverse transcriptase inhibitor 
NNRTI: non nucleoside reverse transcriptase inhibitor 
 
Figure 3: : Ratio of HIV-1 infection with both (A) wild-type (B) and drug 
resistance virus among subjects with recent HIV-1 and subjects who are 
potential transmitters by HIV-1 subtype. 
 
Table 1: Patient characteristics and prevalence of risk factors for primary 
resistance mutations in antiretroviral naive testing seekers in South Brazil 
 OR: odds ratio 
P: p-value 
MSM: man who have sex with man 
MSW: man who have sex with woman 
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Table 2: Comparison of primary resistance mutations by HIV subtypes in 
newly diagnosed antiretroviral naive individuals in South Brazil 
NRTI: nucleoside reverse transcriptase inhibitor 
NNRTI: non nucleoside reverse transcriptase inhibitor 
PI: protease inhibitor 
a. One patient was infected with a NRTI and PI resistant virus 
b. Comparison NRTI and NNRTI only.  
 
Table 3: HIV drug resistance mutations detected among newly identified 
HIV cases by subtypes 
a: Recent HIV infection 
NRTI: nucleoside reverse transcriptase inhibitor 
NNRTI: non nucleoside reverse transcriptase inhibitor 
PI: protease inhibitor 
 
Table 4 : Estimated proportion of HIV subtype B and C transmission in the 
population. 
Sublegend:  
• *Assumes that 4.3 of Subtype B and 5% of the population of Subtype C 
has 0% transmission efficiency due to drug resistance.  
• **Statistical test for the comparison of proportions. 
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 Figure 1.   
 
1255 HIV Testing
149 HIV Ab+1106 HIV Ab‐
1106 RNA ‐/Ab‐
HIV Negative
15 Recent Infections 134 Long‐term 
Infections
15  Sequences Analysed
1 Resistant Case 11 Resistant Cases
0  Not Sequenced 99 Sequences Analysed 35  Not 
Sequenced
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Figure 2. 
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Figure 3  
 
A. Overall 
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B. Wild type only 
 
0,00
0,30
0,14
0%
20%
40%
60%
80%
100%
120%
B C Mosaics
Subtype
Pe
rc
en
ta
ge
 o
f S
ub
je
ct
s
0,00
0,05
0,10
0,15
0,20
0,25
0,30
0,35
R
at
io
 o
f R
ec
en
tly
 In
fe
ct
ed
to
 P
ot
en
tia
l T
ra
ns
m
itt
er
s
Recently infected Potential tramistters Ratio
 
 
 56
Table 1.  
Mutation n (%) 
Characteristic Total n (%) No Yes 
OR(95% CI) P 
Age (years)      
 18 – 32 55 (48) 48 (87) 7 (13) 1.00  
 33 – 65 59 (52) 54 (91) 5 (9) 0.67 (0.2 – 2.1) 0.48 
Gender      
 Male 62 (54) 56 (90) 6 (10) 1.00  
  Female 52 (46) 46 (88) 6 (12) 1.22 (0.3 – 3.7) 0.72 
Schooling       
  < 8 years 55 (49) 51 (93) 4 (7) 1.00  
  > 8 years 58 (51) 50 (86)  8 (14) 2.65 (0.7 – 9.0) 0.11 
Marital status      
  Married 60 (53) 52 (87) 8 (13) 1.00  
  Not married 54 (47) 50 (92) 4 (8) 0.57 (0.1 – 1.8) 0.35 
Exposure category      
 Man who have sex with man (MSM) 17(16) 16 (94)       1 (6) 1.00  
 Man who have sex with woman (MSW) 41(39) 36 (88) 5 (12) 2.74 (0.3 – 27.7) 0.37 
 Heterosexual women  47(45) 41 (87) 6 (13) 2.80 (0.3 – 24.6) 0.35 
Have an HIV infected partner      
  No 91 (80) 81 (87) 10 (13) 1.00  
   Yes 23 (20) 21 (91) 2 (9) 1.09 (0.2 – 4.2) 0.90 
Ulcer or sores on genitals (last 12 
months)      
  No 102 (89) 92 (90) 10 (10) 1.00  
   Yes 12 (11) 10 (83) 2 (17) 2.75 (0.6 - 11) 0.17 
Number of sex partners in the last year  
           0 – 1 
           > 2 
65 (57) 
49 (43) 
58 (89) 
44 (90) 
 
7 (11) 
5 (10) 
1.00 
0.99 (0.3 – 3.1) 0.99 
Unprotected sex events in the previous     
3 months      
Previous HIV test      
 No 37 (33) 34 (92) 3 (8) 1.00  
 Yes 76 (67) 67 (88)  9 (12) 1.25 (0.4 – 4.3) 0.72 
HIV infection stage      
 Acute & ecent 15 (13) 14 (93) 1 (7) 1.00  
 Chronic 99 (87) 88 (89) 11 (11) 2.12 (0.3 – 17.5) 0.49 
HIV subtype      
 B 31 (27) 25 (81) 6 (19) 1.00  
 C 72 (63) 68 (95) 4 (5) 0.47 (0.1 – 1.7) 0.25 
 Mosaic 11 (10) 9 (82)  2 (18) 1.95 (0.4 – 10.0) 0.42 
RNA viral load (copy numbers per mL)       
 <1000 9 (8) 9 (100) 0 (0) --  
 50,000 -1000 55 (51) 48 (87) 7 (13) 1.00  
 >50,000 44 (41) 39 (88) 5 (12) 1.08 (0.3 – 3.4) 0.90 
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Table 2.  
Antiretroviral class  
n (%) HIV subtype 
No. of patients 
with any  mutation
n (%) NRTI NNRTI PI 
P 
 B (n=31) 6 (19,3) 5 (80) a 1 (20) 1a 0.03 b
 C (n=72) 4 (5,5) 0 (0) 4 (100) 0  
Mosaics (n=11) 2 (18,0) 0 (0) 2 (100) 0  
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Table 3.  
 
 HIV Subtype NRTI NNRTI PI 
1 B M41L  L90M 
2 B M184V   
3a B  K103N   
4 B V118I   
5 B L210W   
6 B T69NST   
7 C  K103N  
8 C  K103N  
9 C  V108I  
10 C  V108I  
11 mosaic  K103N  
12 mosaic  K103N  
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Table 4. 
HIV 
subtype 
HIV 
subtype 
prevalence 
% 
Drug 
resistance 
prevalence 
% 
Potential 
transmitters  of  
resistant virus * 
Potential 
transmittters 
of wild-type 
virus 
Transmission 
efficiency 
ratio  of     
wild-type 
virus 
Risk P** 
B 27 19 27% x 0.19= 5.2% 
27 – 5.2 = 
21.8% 0.30 
21.8% x 0.3 = 
6.54 
 
C 63 5 63% x .055= 3.4% 
63 – 3.4 = 
59.6% 0.14 
59.6% x 0.14= 
8.34 .17 
Mosaic 10 18 10 x 0.18= 1.8% 
10 - 1.8= 
8.2% 0.00 
8.2% x 0=       
0 
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CONCLUSÕES 
 
1. Estratégias laboratoriais que utilizam ELISA de quarta geração 
apresentaram alto desempenho analítico em nosso estudo.  
2. A prevalência de infecções agudas na população que busca de 
testagem e aconselhamento para o HIV na região sul foi de 1.7%.  
3. Indivíduos que se apresentam para testagem na fase aguda da 
infecção resultam em casos falso-negativos no esquema de 
triagem que utiliza apenas ELISAS de terceira geração. A utilização 
de testes confirmatórios baseados na detecção de anticorpos não 
soluciona o problema. 
4. Na região sul do Brasil o HIV-1 subtipo C e formas circulantes 
recombinantes (FRC), juntos, são responsáveis por 78% das 
infecções, com o subtipo C representando 63% das infecções. 
5. A prevalência da resistência primária é relativamente baixa na 
região sul como também a existência de cepas multi- resistentes.  
6. A presença de mutações de resistência varia de acordo com o 
subtipo. O HIV subtipo C está associado, em nosso estudo, 
exclusivamente a mutações associadas a classe de anti-retrovirais 
inibidores da transcriptase reversa não nucleosídeos (ITRNN). 
7. Por meio da utilização de cálculos epidemiológicos como modelo 
para estimar a expansão dos subtipos circulantes na região, pode-
se estimar a vantagem competitiva do HIV subtipo C a nível 
populacional.  
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